Study wrapper · #642
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
Editor's note
This is a human clinical comparison of the peptide anxiolytic selank against the benzodiazepine phenazepam in 60 patients with phobic-anxiety and somatoform disorders. Researchers reported pronounced anxiolytic and mild nootropic effects of selank, with the anxiolytic effect persisting about a week after the last dose and a positive impact on quality of life. The abstract does not describe randomization or blinding, so I classify it as a controlled clinical comparison rather than a formal RCT. For Selank, this is part of a small cluster of Russian clinical studies that underpin its regulatory approval there, and it is among the more decision-relevant items in this batch. Weigh it as suggestive human evidence tempered by design limits: modest sample, likely open-label, single reporting group, and outcome scales not fully specified in the abstract. Evidence is best rated mixed — supportive in direction but not from the kind of blinded, replicated trials that would firm up an efficacy claim.
Plain-language abstract
This study in people compared the peptide selank with a standard tranquilizer, phenazepam, in 60 patients who had anxiety- and body-symptom-related disorders. The goal was to see how well selank reduced anxiety and how well patients tolerated it. The researchers reported that selank produced a clear anti-anxiety effect and a mild memory- and focus-supporting effect. Notably, the calming benefit was said to last for about a week after the final dose, and patients' quality of life improved. The report did not state that patients were randomly assigned or that the assessors were kept unaware of who received what, and the study was fairly small and from a single group. That means the results are encouraging but not the strongest kind of proof. It adds to a small body of human research behind selank's approval in Russia, while leaving room for larger, more rigorous trials to confirm the effect.